21 May 2013
Keywords: merck, co, pays, premium, buy, sirna, therapeutics
Article | 06 November 2006
*p US pharmaceutical major Merck & Co is to pay a premium of nearly 102%
to acquire Sirna Therapeutics, a publicly-held biotechnology ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 November 2006
20 May 2013
© 2013 thepharmaletter.com